04:28 AM EDT, 03/30/2026 (MT Newswires) -- Eli Lilly ( LLY ) will collaborate with Insilico Medicine in a deal that leverages artificial intelligence to boost drug discovery and development, Insilico said Sunday.

The deal grants Lilly an exclusive worldwide license to a portfolio of oral therapeutic programs in preclinical development.

Under the terms of the deal, Insilico said it's eligible to receive an $115 million upfront payment, followed by development, regulatory, and commercial milestones that could bring the total deal value to about $2.75 billion, plus tiered royalties on future sales.

The companies will also jointly advance multiple research and development programs targeting disease areas selected by Lilly.